Medindia

X

Infiltrating to the Core of the Gray Matter in Parkinson's Disease Treatment

by Nancy Needhima on  April 6, 2012 at 5:33 PM Research News   - G J E 4
Agent under review for use in PET imaging fights neuronal death to ease Parkinsonian symptoms in animal models, states study in the Journal of Experimental Medicine published on April 2nd.
Infiltrating to the Core of the Gray Matter in Parkinson's Disease Treatment
Infiltrating to the Core of the Gray Matter in Parkinson's Disease Treatment
Advertisement

The movement-related symptoms of Parkinson's disease, including muscle rigidity and tremors, are caused by the loss of dopamine-secreting neurons in the brain. Current therapies aim at increasing and maintaining dopamine levels to correct these motor impairments. However, these approaches do not address the underlying neuronal death that initiated the disease.

Advertisement
David Finkelstein, Kevin Barnham, and colleagues at the University of Melbourne find that the PET imaging agent CuII(atsm) reverses the neurotoxicity that destroys dopamine-secreting neurons. Improvements in motor skills and memory were observed after treatment in four unique animal models of Parkinson's disease. The authors suggest this compound functions as a scavenger of peroxynitrite, whose accumulation is known to promote neuronal death.

These results point to a potential strategy to restore motor and cognitive function in Parkinson's disease patients by reviving neuronal function rather than solely masking symptoms.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All